Zimmer Biomet awards highlight focus on orthopedic tech and digital tools

Zimmer Biomet Holdings (ZBH) has drawn fresh investor interest after receiving three Healthcare Asia Medtech Awards 2026, recognizing its iodine-treated hip implants and WalkAI recovery monitoring platform, alongside broader orthopedic and surgeon engagement capabilities.

Despite recognition for its orthopedic and digital health tools, Zimmer Biomet’s recent share price performance has been subdued, with a 30 day share price return of about a 10% decline and a 1 year total shareholder return of about a 21% decline, suggesting sentiment has been cautious rather than momentum driven.

If this kind of medtech story interests you, it could be worth widening your watchlist using a focused screener to uncover other healthcare names applying AI at scale, including 34 healthcare AI stocks

With awards piling up but the share price lagging, Zimmer Biomet trades at about a 48% intrinsic discount and around a 16% gap to analyst targets. Is this a window of opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 14% Undervalued

Zimmer Biomet’s most followed narrative pegs fair value at $103 against a last close of $88.62, framing today’s price as a material discount.

The company's focused investment in digital health, robotics, and data-driven surgical solutions (including the ROSA and upcoming Monogram platforms) is increasing adoption of premium offerings, enabling margin expansion due to product mix and driving recurring revenues through connected care ecosystems, supporting higher net margins and earnings predictability.

Curious what earnings path and margin profile need to line up for that fair value to hold? The narrative leans on disciplined growth assumptions, richer profitability, and a future P/E that still sits below the sector’s current average.

Result: Fair Value of $103 (UNDERVALUED)

However, there is still real execution risk, with pricing pressure and tougher competition in robotics and core orthopedics both capable of undermining this undervalued thesis.

Next Steps

With sentiment clearly mixed, it makes sense to move quickly, review the key data points yourself, and weigh both sides of the story using 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Zimmer Biomet has your attention, do not stop here. A broader watchlist gives you more ways to spot opportunities before the crowd catches on.

• Target potential mispricing by scanning companies that our models flag as attractively valued using the 63 high quality undervalued stocks.
• Build a steadier income stream by reviewing companies highlighted as 12 dividend fortresses.
• Prioritize resilience by focusing on companies surfaced in the 63 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.